Patterson Cos. (PDCO) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items. Patterson Cos., which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1.72 billion for the quarter ended April 2024, surpassing the Zacks Consensus Estimate by 0.02%. This compares to yearago revenues of $1.72 billion. The company has topped ...

Financial Performance - Fourth quarter net sales increased 01% year-over-year to $172 billion, but internal sales decreased 05%[16] - Q4 GAAP earnings were $074 per diluted share, and adjusted earnings were $082 per diluted share, negatively impacted by $004 per diluted share due to a cybersecurity attack[17] - Fiscal year 2024 GAAP earnings reached $198 per diluted share, with adjusted earnings at $230 per diluted share[17] - The company returned $3279 million to shareholders in FY 2024 through dividends and share repurchases[16] Sales Breakdown - Consumables sales increased by 32% to $138 billion, with internal sales growth of 28%[21] - Equipment sales decreased by 110% to $2491 million[21] - Value-Added Services and other sales decreased by 101% to $970 million, with internal sales decreasing by 157%[21] - Patterson Dental's total sales decreased by 38%, with consumables increasing by 37%[27] - Patterson Animal Health's total sales increased by 31%, with consumables increasing by 31%[32] Fiscal 2025 Guidance - The company projects fiscal 2025 GAAP earnings to be in the range of $200 to $210 per diluted share[18] - Non-GAAP adjusted earnings for fiscal 2025 are expected to be between $233 and $243 per diluted share, excluding deal amortization expenses of approximately $291 million ($033 per diluted share)[18, 38] Cash Flow - Free cash flow for the twelve months ended April 27, 2024, was $1713 million, compared to $1798 million for the previous year[35] - The company paid $983 million in dividends and repurchased $2295 million in shares year-to-date[36] - As of the end of the fourth quarter of fiscal 2024, Patterson had $500 million remaining on its share repurchase authorization[43]

PATTERSON COMPANIES REPORTS FISCAL 2024 FOURTH QUARTER AND YEAR END OPERATING RESULTS PATTERSON COMPANIES | 1031 Mendota Heights Road | Saint Paul, MN 55120 NEWS RELEASE Reported net income attributable to Patterson Companies, Inc. for the fourth quarter of fiscal 2024 was $67.0 million, or $0.74 per diluted share, compared to $75.0 million, or $0.77 per diluted share, in the fourth quarter of fiscal 2023. Adjusted net income 1 attributable to Patterson Companies, Inc., which excludes deal amortization, tot ...

Loading... Analysts expect the Saint Paul, Minnesota-based company to report quarterly earnings at 83 cents per share, down from 84 cents per share in the year-ago period. Patterson Companies is expected to post revenue of $1.71 billion, compared to $1.72 billion a year earlier, according to data from Benzinga Pro. On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share. Benzinga readers can access the latest analyst ratings on the Analy ...

Bearing this in mind, let's now explore the average estimates of specific Patterson Cos. metrics that are commonly monitored and projected by Wall Street analysts. Analysts expect 'Net Sales- Dental supply' to come in at $673.11 million. The estimate indicates a change of -1.5% from the prior-year quarter. The consensus EPS estimate for the quarter has been revised 5.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their ini ...

The company missed on earnings in the last reported quarter. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, missed in one and met in the other, delivering an average surprise of 2.02%. Stocks Worth a Look Q4 Estimates Factors to Note In the fiscal third quarter, sales in the Animal Health segment decreased 0.2% on a year-over-year basis. On its third-quarter fiscal 2024 earnings call, the company stated that the production animal business remained strong while the compa ...

Price Performance Currently, Patterson Companies carries a Zacks Rank #4 (Sell). Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX's earnings surpassed estimates in each of the trailing four quarters, with the average being 7.5%. Patterson Dental practice management software customers now expected to have additional electronic insurance processing and electronic patient statement solutions available via DentalXChange. Significance of the Launch Pe ...

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Patterson Cos. Would post earnings of $0.60 per share when it actually produced earnings of $0.59, delivering a surprise of -1.67%. Over the last four quarters, the company has beaten consensus ...

Significance of the Launch With Wellfit's healthcare financial technology applications, Patterson CarePay+ is expected to provide patients and dental practices with a frictionless payment experience, allowing customization and patient choice. Per management, patients (both with and without other dental insurance) can now be offered alternative payment options via customizable dental plans, patient financing options and payment processing with the Patterson CarePay+ solution. For dental offices, Patterson Ca ...

Ivan Pantic One of the most difficult aspects of investing is the fact that the market can be rather inefficient from time to time. It might seem efficient, for instance, to push shares of a business down when that business is seeing mixed or even worsening financial performance. But when the shares of the company in question are already trading at really low levels, further downside becomes irrational unless you are planning for a steep decline in revenue or profits moving forward. One company that has see ...